FAK-Copy-Gain Is a Predictive Marker for Sensitivity to FAK Inhibition in Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Targeted therapy is effective for cancers with copy-gain drug-target genes.
• Identifying new predictive marker genes is crucial for advancing targeted cancer treatments.

Purpose of the Study:

• To investigate the correlation between drug sensitivity and copy gain of candidate target genes in NCI-60 cancer cells.
• To identify potential predictive markers for targeted therapy.

Main Methods:

• Tested sensitivity to target drugs in NCI-60 cells with copy gains of eight candidate genes.
• Utilized FAK inhibitor 14 (F14) and FAK-knockdown experiments.
• Performed expression-profiling analyses and a mouse xenograft model.

Main Results:

• Breast cancer cells with Focal Adhesion Kinase (FAK)-copy-gain showed significantly higher sensitivity to FAK inhibitor 14 (F14).
• F14 treatment or FAK-knockdown induced apoptosis specifically in FAK-copy-gain breast cancer cells.
• FAK/AKT signaling is implicated in the apoptotic effect; F14 demonstrated significant growth inhibition in a mouse xenograft model for FAK-copy-gain tumors.

Conclusions:

• FAK copy-gain may serve as a predictive biomarker for FAK inhibition therapy in breast cancer.
• This finding supports the development of targeted therapies based on genetic alterations.